Offer Request Form

Order list is empty

Shikari® (S-ATR) Anti-Rituximab ELISA w/confirmation

Enzyme immunoassay for the quantitative determination of antibodies to of Rituximab (Rituxan®, Mabthera®) in serum and plasma with confirmation.

This kit has been especially developed for the quantitative antibodies to Rituximab in serum and plasma samples

Rituximab (Rituxan®, Mabthera®) was associated to the development of anti-rituximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug (Rituxan®, Mabthera®)  .This might lead to severe complications. This kit can be efficiently used for monitoring anti- rituximab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-rituximab antibodies. 

All SHIKARI® ELISA kits are suitable for biosimilar work. 

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact techsupport@matriksbiotek.com

Required Volume (µl) 20
Total Time (min) 140
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 7,5
Spike Recovery (%) Between 85-115
Shelf Life (year) 1
Assay type Quantitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Instructions For Use Download
Safety Data Sheet (SDS) Download
Validation Report Download

Publications with this drug

# File Action
Sinha, Aditi, et al. "Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects." Nephrology Dialysis Transplantation 38.4 (2023): 939-949. Visit Link
Chen, Yewei, et al. "Population pharmacokinetics of rituximab in pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome." Frontiers in Pharmacology 12 (2021): 725665. Visit Link
Liu, Shu, et al. "Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes." Clinical and Translational Science 15.3 (2022): 680-690. Visit Link
Liu, Shu, et al. "Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2." Acta Pharmacologica Sinica 42.4 (2021): 641-647. Visit Link
Bai, Yunfei, et al. "Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody." Frontiers in Immunology 14 (2023): 1121705. Visit Link
Chen, Yewei, et al. "Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: a prospective pharmacokinetic-pharmacodynamic study." Frontiers in Pharmacology 14 Visit Link
Abdullah, Iqbal Muaafi, et al. "The Diagnostic Value of Anti-rituximab Ab in Iraqi Patient with Chronic Lymphocytic Leukemia." International journal of health sciences 6.S6: 3005-3013. Download